TMS therapy cost in the UK: NHS, private & abroad compared

UK private TMS clinics typically charge £6,000–£8,000 for a standard 30–36 session course of repetitive TMS for depression. NHS rTMS is free but is only commissioned in a few regions and waiting lists commonly exceed 12–24 months. Accelerated rTMS abroad in Vilnius costs €2,900 for the full 30-session course delivered in one week.

rTMS for treatment-resistant depression was recommended by NICE in interventional procedures guidance (IPG542, 2015) and is commissioned by a small number of NHS trusts — including services in London (South London and Maudsley, Camden & Islington), Cambridge, Northampton, Oxford Health, and a few sites in Scotland. Outside those catchments rTMS is not routinely available on the NHS at all. Where it is commissioned, an Individual Funding Request (IFR) or specialist referral is usually needed, and waiting times from GP referral to first session typically run 12–24 months, with some trusts reporting 2-year-plus lists.

UK private clinics almost universally deliver the FDA/NICE-aligned standard protocol: high-frequency (10 Hz) repetitive TMS to the left dorsolateral prefrontal cortex, ~3,000 pulses per session, one session per day, five days a week, for six weeks (30–36 sessions total). Sessions last 19–37 minutes depending on whether intermittent theta-burst stimulation (iTBS) is used. Treatment is preceded by a motor-threshold mapping session and a psychiatric assessment.

Per-session pricing at UK private clinics is usually £180–£250, with a full course of 30–36 sessions costing £6,000–£8,000. Some London clinics charge up to £10,000. Initial psychiatric assessment is usually £250–£500 extra and motor-threshold mapping may be billed separately.

Coverage is inconsistent. Bupa, AXA Health, Aviva, and Vitality may cover rTMS for treatment-resistant depression when prescribed by a covered consultant psychiatrist and pre-authorised, but many policies still exclude it or require documented failure of two or more antidepressant trials at adequate dose and duration. Always confirm in writing with your insurer before booking.

Accelerated rTMS delivers multiple sessions per day (typically 5–10 sessions/day, spaced 50+ minutes apart) over 5 consecutive days instead of one session per day for six weeks. The total pulse dose is comparable to — or higher than — a standard course. The strongest evidence base is the Stanford SAINT/SNT protocol (Cole et al., American Journal of Psychiatry 2022; NCT03240692), which used iTBS at 90% resting motor threshold, 1,800 pulses per session, 10 sessions per day for 5 days, with fMRI-guided targeting of the L-DLPFC. At Neuropulsas the accelerated course compresses the full 30-session dose into one week using the same iTBS parameters validated in the SAINT and Williams Lab work.

Across published trials, response and remission rates for accelerated iTBS are at least equivalent to the standard 6-week course, and the SAINT trial reported remission in roughly 79% of treatment-resistant participants at 4 weeks post-treatment versus ~13% with sham. Standard 6-week rTMS in routine care reports response rates of 45–55% and remission of 30–40% (NeuroStar registry; Carpenter et al.). The key practical difference is speed: accelerated patients reach the same or better clinical endpoint in 1 week instead of 6, which matters when someone is acutely unwell or cannot take six weeks off work.

Yes. The safety profile of accelerated iTBS in published trials mirrors standard rTMS: most common side effects are transient scalp discomfort at the coil site and mild headache, both usually resolving within hours. Seizure risk for iTBS at 90% RMT remains in the same order as standard rTMS — roughly 1 in 30,000 sessions or lower — and no seizures were reported in the SAINT trial. There is no anaesthesia, no sedation, no cognitive side effects, and patients drive themselves home. The same exclusion criteria apply: ferromagnetic implants in the head, cochlear implants, history of epilepsy, or unstable cardiac devices.

Lower clinical operating costs (staff salaries, premises, regulatory overhead, indemnity) in Lithuania compared to the UK, combined with an accelerated schedule that uses one room and one technician far more efficiently than six weeks of single daily sessions. The equipment (Magstim/MagVenture/Neurosoft figure-of-eight coils), CE/FDA clearances, motor-threshold protocol, and stimulation parameters are the same as those used in NHS and UK private services.

rTMS is non-invasive, requires no anaesthesia, and patients walk in and out of each session — there are no flying restrictions before or after treatment and no recovery period. For UK patients a return flight to Vilnius plus a week in a city-centre hotel typically adds £600–£1,000. Treatment is overseen by a psychiatrist and a neurologist, English is spoken throughout, and a written treatment report is provided to share with your UK GP or psychiatrist for ongoing care.

Yes. Many UK patients keep their NHS GP and psychiatrist for ongoing antidepressant management and mental-health follow-up, and use accelerated rTMS abroad purely as a one-week intervention. Neuropulsas issues a full clinical report (protocol used, motor threshold, sessions delivered, response measurement) that your UK clinician can file in your NHS record.